Annual Report · 10-K

MiMedx Group, Inc

MDXGNASDAQEQUITYCurrent

Annual Report

Filed Feb 25, 2026Accepted Feb 25, 2026, 4:01 PM ESTCIK 1376339Accession 0001376339-26-000011

Company context

Surgical Markets Offer a Large, Expanding Opportunity Outside of Wound Care 1 - Life Science Intelligence, U.S. Surgical Procedure Volumes Database: inpatient and outpatient procedures, 2024. 2 - Calculated using Definitive Healthcare Database, LSI Procedural Data, published orthopedic market research data and related journals, surgeon validation, and Sanara estimates. | 13 | LARGE SURGICAL MARKET ~92 million Surgical procedures performed in the US each year1 ~23 million General surgery procedures performed in the US each year1 +$4B Incremental addressable market unlocked by the Sanara acquisition2 GROWING MIMEDX PRESENCE 15% Surgical sales growth based upon LTM Q3:26 vs. LTM Q3:25 8 studies Underway across surgical disciplines, with 5 published since May 2025 Expanding Offering Non-placental derived products, like HELIOGEN® and G4Derm® Plus augmenting Surgical growth Surgical Complications Burden Providers and Payors, Creating Demand for Products That Improve Outcomes

Current securities

MDXGNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

MIMEDX GROUP, INC. · 10-K · Filed 2026-02-25

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol: MDXG
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000137633926000011 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.